Summary
Advances in next-generation sequencing and multi-omics technologies have revolutionized cancer research, enabling unprecedented insights into tumor biology. The Translational Cancer Bioinformatics group at RBCT develops computational tools, pipelines, and infrastructure to leverage these technologies effectively. Using multi-omics approaches, we investigate key regulatory mechanisms in cancer to drive discoveries for precision oncology and therapeutic development.
Major Research Goals
1. Data Infrastructure & Tools
Build scalable bioinformatics infrastructure and adapt nextflow/nf-core pipelines for cancer research.
2. Regulatory Mechanisms in Cancer
Study transcriptional, post-transcriptional, and epigenetic regulation in tumors.
3. Anti-Tumor Drug Discovery
Identify druggable targets and predict therapy resistance using integrative multi-omics data.
Highlights
- Establishing a platform (BRAT) to enable scalable and reproducible multi-omics analysis using nextflow/nf-core pipelines.
- Implementing workflows for identifying biomarkers associated with pancreatic cancer progression and therapy resistance.
- Built tools for transcription factor binding site prediction.
Outlook
Advance open-source tools to support multi-omics data processing and integration for clinical research.
Strengthen partnerships for anti-tumor drug discovery by integrating computational insights into experimental workflows.
Develop computational tools to connect research discoveries with clinical applications, enabling noval cancer treatments.